Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 7/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15718299 | 0.90 | GRIN1 (0.40) | GPBAR1KCNH2GRIN1GRIN2BSCN5A | |
| SCHEMBL15764750 | 0.88 | KCNH2 (0.40) | GPBAR1PTGS2PTGS1KCNH2PTGDR2 | |
| SCHEMBL15718306 | 0.87 | NTRK1 (0.40) | GPBAR1GRIN1GRIN2BSCN5ASCN9A | |
| SCHEMBL15718173 | 0.85 | GPBAR1 (0.38) | GPBAR1PTGDR2GRIN1GRIN2B | |
| SCHEMBL15717380 | 0.84 | RET (0.39) | GPBAR1KCNH2GRIN1GRIN2B | |
| SCHEMBL15764704 | 0.83 | GRIN1 (0.38) | GPBAR1PTGDR2GRIN1GRIN2B | |
| SCHEMBL15717611 | 0.83 | KCNH2 (0.44) | GPBAR1PTGS2PTGS1KCNH2IDO1 | |
| SCHEMBL15717832 | 0.80 | ATR (0.39) | KCNH2 | |
| SCHEMBL15739559 | 0.80 | SRC (0.33) | KCNH2KDM4EGAANPSR1 | |
| SCHEMBL15717119 | 0.79 | MLYCD (0.39) | GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190030009-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CRYPTOSPORIDIOSIS | NOVARTIS AG (CH) | 2019-01-31 | — | — | US | claimed |
| EP-3405468-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CRYPTOSPORIDIOSIS | Novartis AG (CH) | 2018-11-28 | — | — | EP | claimed |
| EP-2925757-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2017-10-04 | — | — | EP | claimed |
| WO-2017125898-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CRYPTOSPORIDIOSIS | NOVARTIS AG (CH) | 2017-07-27 | — | — | WO | claimed |
| US-9556169-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2017-01-31 | — | — | US | claimed |
| US-20160333012-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2016-11-17 | — | — | US | claimed |
| US-20150344471-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2015-12-03 | — | — | US | claimed |
| EP-2925757-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | Novartis AG (CH) | 2015-10-07 | — | — | EP | claimed |
| US-20150011522-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2015-01-08 | — | — | US | claimed |
| US-8871754-B2 | Compounds and compositions for the treatment of parasitic diseases | IRM LLC (BM) | 2014-10-28 | — | — | US | claimed |
| US-20140155367-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2014-06-05 | — | — | US | claimed |
| WO-2014078802-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2014-05-22 | — | — | WO | claimed |
| US-20190030009-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CRYPTOSPORIDIOSIS | NOVARTIS AG (CH) | 2019-01-31 | — | — | US | disclosed |
| US-9926314-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2018-03-27 | — | — | US | disclosed |
| US-9926314-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2018-03-27 | — | — | US | disclosed |
| US-9926314-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2018-03-27 | — | — | US | disclosed |
| US-20140155367-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2014-06-05 | — | — | US | disclosed |
| US-20140155367-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2014-06-05 | — | — | US | disclosed |
| WO-2014078802-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014078802-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2014-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344471-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | MAPT, CYP11B1, CYP11B2 | GPBAR1 43/4885PTGS2 167/4885PTGS1 110/4885 |
| US-20150011522-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | MAPT, CYP11B1, CYP11B2 | GPBAR1 43/4885PTGS2 167/4885PTGS1 110/4885 |
| US-20140155367-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | MAPT, CYP11B1, CYP11B2 | GPBAR1 43/4885PTGS2 167/4885PTGS1 110/4885 |
| US-20160333012-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | MAPT, CYP11B1, CYP11B2 | GPBAR1 43/4885PTGS2 167/4885PTGS1 110/4885 |
| US-20190030009-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CRYPTOSPORIDIOSIS | PI4KA, PI4K2A, PIP4K2A | GPBAR1 1094/4885PTGS2 1512/4885PTGS1 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.